Tenalisib is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to GlobalData, Phase II drugs for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) have a 17% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tenalisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tenalisib overview

Tenalisib (RP-6530) is under development for the treatment of relapsed or refractory hematologic malignancies including relapsed and chronic lymphocytic leukemia, diffuse large B-cell lymphoma and Hodgkin Lymphoma, refractory cutaneous T-Cell lymphoma, peripheral T-Cell lymphomas (PTCL), follicular lymphoma, marginal zone lymphoma, waldenstrom macroglobulinemia, small lymphocytic lymphoma, triple negative breast cancer, acute myelocytic leukemia, solid tumors and ovarian cancer. It is administered through oral route, topical and inhalational route. The drug candidate is a dual phosphoinositide-3 kinase (PI3K) delta/gamma inhibitor and Salt-Inducible Kinase 3 (SIK3) inhibitor. It was also under development for asthma and chronic obstructive pulmonary disease (COPD), airway inflammation, arthritis, and multiple myeloma.

The drug candidate was under development for the treatment of vitiligo.

Rhizen Pharmaceuticals overview

RhizenPharmaceuticals (RhizenPharma), a subsidiary of Alembic Pharmaceuticals Ltd, is a biopharmaceutical company that discovers and develops small molecule drugs. The company’s research products include c-Met inhibitors, selective P13K inhibitors, CRAC channel inhibitors and GPR 119 agonist. It conducts research in the therapeutic areas of oncology, immune inflammation and metabolic disorders such as diabetes and obesity. RhizenPharma’s products find application in the treatment of diseases such as solid tumors, B cell lymphomas, hematological malignancies, asthma, diabetes and chronic obstructive pulmonary disease, among others. It collaborates with other pharmaceutical companies. Rhizenis headquartered in La Chaux-de-Fonds, Switzerland.

For a complete picture of Tenalisib’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.